Articles by Cody R. Barnett, MRA Director of Communications
Creating a New Generation of Melanoma Models
We all can remember the eruption that happened when our 1st grade science teacher combined vinegar and baking soda together to represent a volcano. In some ways, this is just like experiments that take place every day in the search for better treatments, and ultimately a cure, for melanoma. In both instances, the researcher uses models to represent systems and phenomena that would otherwise be difficult or unethical to touch, see, or manipulate. Models are powerful things and we use them every day to make things easier to understand. In science, modeling is an essential component of our scientific process.
Introducing Clinical Trial Navigator: Start Searching Today
At MRA, we know that advancing science is our best bet in the fight against melanoma. More than 87,000 people in the US will be diagnosed with melanoma this year, and with these numbers on the rise, researchers are working harder than ever to find new and better treatment options. In fact, there are over 300 clinical trials happening in melanoma right now.
Connecting the Dots – Clinical Trials and Patient Engagement
MRA is thrilled to announce the launch of the Melanoma > Exchange, a melanoma treatment and research focused discussion group and support community. Through the Melanoma > Exchange, anyone touched by Melanoma can find support, ask questions, and build community among people who share a similar experience.
“Hands down, I’m alive today because of clinical trials”
Jamie Goldfarb didn’t think of herself as having cancer. Yes, she had been diagnosed with Stage II melanoma four years earlier and Stage III the following year, but the surgeries to remove it had been successful. The PET scans that followed had been normal. This wasn’t supposed to be happening. Jamie was now a tired new mom with an eleven-week old baby and she was ready to get back to work. But, her world would turn upside down when she learned that not only was melanoma back, but it had progressed to Stage IV and spread to her liver and pancreas.
Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment
The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.
MRA Raises Millions of Dollars for Groundbreaking Melanoma Research
Normally, when people are at a Sotheby’s auction, they come to bid on beautiful and rare art. On Nov. 2nd, however, more than 240 people came together at Sotheby’s Headquarters in New York City to raise their paddle in the fight against melanoma. Together, participants raised over $20 million to further advance melanoma research.
“Seeing his Family Grow-Up Thanks to the Promise of Clinical Trials”
In August 2012, T.J. Sharpe walked into the emergency room with a fever. He’d been ill for a couple of days and didn’t want to get his four-week old son sick if he could avoid it. Sixteen days later, he left a full 30 pounds lighter and with a stage IV melanoma diagnosis.
Safe and Sound: Balancing Safety with Innovation in American Sunscreens
Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?
Are Nanoparticles the Answer to the Question: Is it Working? An Interview with MRA Young Investigator, Dr. Ashish Kulkarni
When we think about cancer researchers, we don’t always think of engineers. Dr. Ashish Kulkarni proves that maybe, we should. His pioneering work as a chemical engineer is helping us answer the critical, yet difficult to answer question that is at the forefront of every patient’s mind as they start treatment: ‘is it working?’
A Mother’s Perspective: New Options for Pediatric Melanoma
When Cheryl Trocke’s nine-year old son Graham was diagnosed with melanoma four years ago, she quickly learned that when it comes to kids, there were no great treatment options and that care can vary greatly based on where your child is treated. After surgically removing the primary tumor, Graham’s doctors suggested a treatment plan of ‘wait and see.’
About the Author
Cody R. Barnett, MRA Director of Communications
Cody R. Barnett joined the Melanoma Research Alliance (MRA) as Director of Communications in August of 2017. He works to develop and cultivate strategies, messages, and stories that propel MRA’s mission forward. Cody is responsible for media relations, web and social marketing, publications and materials development, and organizational branding. He is committed to using the power of visual, verbal, and written communications to promote MRA as a powerful force for advancing melanoma research.
Before joining the Melanoma Research Alliance, Cody served as Director of Communications at AIDS United, where he directed all internal, public, member, and online communications for the national HIV-focused organization. Previous to this, he managed digital communications for the Robert Wood Johnson Foundation’s Aligning Forces for Quality (AF4Q) initiative.
Cody earned his Master of Public Health (MPH), concentrating in health policy, from The George Washington University Milken Institute School of Public Health in 2013 and a Bachelor of Arts in political science from York College of Pennsylvania.